GAIN THERAPEUTICS, INC Operating Cash Flow
GAIN THERAPEUTICS, INC (GANX) reported Operating Cash Flow of -$9.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.68M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.73M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.62M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.93M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for fiscal 2025 was -$18.47M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for fiscal 2024 was -$18.87M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for fiscal 2023 was -$18.87M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) operating activities for fiscal 2022 was -$14.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$9.41M 10-Q · filed 2026-08-11 | -$14.03M derived: sum of 3 quarters · filed 2026-08-11 | -$18.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$4.73M 10-Q · filed 2026-05-11 | -$9.35M derived: sum of 2 quarters · filed 2026-05-11 | -$14.27M derived: sum of 3 quarters · filed 2026-05-11 | -$19.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$9.54M derived: sum of 2 quarters · filed 2026-03-26 | -$14.64M derived: sum of 3 quarters · filed 2026-08-11 | -$18.47M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$10.03M derived: sum of 2 quarters · filed 2026-08-11 | -$13.85M 10-Q · filed 2025-11-12 | -$17.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.92M 10-Q · filed 2026-08-11 | -$12.38M derived: sum of 3 quarters · filed 2026-08-11 | -$18.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$3.82M 10-Q · filed 2026-05-11 | -$7.28M derived: sum of 2 quarters · filed 2026-05-11 | -$13.35M derived: sum of 3 quarters · filed 2026-05-11 | -$19.11M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$9.53M derived: sum of 2 quarters · filed 2026-03-26 | -$15.29M derived: sum of 3 quarters · filed 2026-03-26 | -$18.87M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$6.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$11.83M derived: sum of 2 quarters · filed 2025-11-12 | -$15.42M 10-Q · filed 2025-11-12 | -$21.08M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$9.34M 10-Q · filed 2025-08-12 | -$15.00M derived: sum of 3 quarters · filed 2025-08-12 | -$18.97M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$3.59M 10-Q · filed 2025-05-14 | -$9.25M derived: sum of 2 quarters · filed 2025-05-14 | -$13.21M derived: sum of 3 quarters · filed 2025-05-14 | -$18.24M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$9.63M derived: sum of 2 quarters · filed 2025-03-27 | -$14.65M derived: sum of 3 quarters · filed 2025-03-27 | -$18.87M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$8.99M derived: sum of 2 quarters · filed 2024-11-14 | -$13.21M 10-Q · filed 2024-11-14 | -$17.11M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$9.24M 10-Q · filed 2024-08-08 | -$13.14M derived: sum of 3 quarters · filed 2024-08-08 | -$16.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$4.22M 10-Q · filed 2024-05-14 | -$8.12M derived: sum of 2 quarters · filed 2024-05-14 | -$11.41M derived: sum of 3 quarters · filed 2024-05-14 | -$16.46M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$7.19M derived: sum of 2 quarters · filed 2024-03-26 | -$12.24M derived: sum of 3 quarters · filed 2024-03-26 | -$14.69M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$8.34M derived: sum of 2 quarters · filed 2023-11-14 | -$10.79M 10-Q · filed 2023-11-14 | -$14.93M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$7.50M 10-Q · filed 2023-08-10 | -$11.64M derived: sum of 3 quarters · filed 2023-08-10 | -$13.84M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$2.45M 10-Q · filed 2023-05-12 | -$6.59M derived: sum of 2 quarters · filed 2023-05-12 | -$8.79M derived: sum of 3 quarters · filed 2023-05-12 | -$12.00M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$6.34M derived: sum of 2 quarters · filed 2023-03-23 | -$9.56M derived: sum of 3 quarters · filed 2023-03-23 | -$12.37M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$5.41M derived: sum of 2 quarters · filed 2022-11-10 | -$8.22M 10-Q · filed 2022-11-10 | -$9.53M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$6.03M 10-Q · filed 2022-08-08 | -$7.34M derived: sum of 3 quarters · filed 2022-08-08 | -$8.09M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$2.81M 10-Q · filed 2022-05-16 | -$4.12M derived: sum of 2 quarters · filed 2022-05-16 | -$4.87M derived: sum of 3 quarters · filed 2022-05-16 | -$5.30M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$2.06M derived: sum of 2 quarters · filed 2022-03-25 | -$2.49M derived: sum of 3 quarters · filed 2022-03-25 | -$3.24M 10-K · filed 2022-03-25 |
| 2020-09-30 | -$755.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.18M derived: sum of 2 quarters · filed 2021-11-12 | -$1.93M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$424.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.18M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$752.82K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |